2026 continues to gain momentum with strategic acquisitions and funding rounds driving growth across surgical robotics, AI diagnostics, and next-generation therapeutic devices. Capital is flowing to support commercialization, clinical expansion, and innovation that is set to reshape patient care. Read more below.
Boston Scientific announced the acquisitions of Penumbra and Valencia Technologies
Boston Scientific agreed to acquire Penumbra in a deal worth around $14.5B, a move that will expand the medtech giant’s offerings in ‘fast-growing segments’ within the vascular care space.
The company also announced that it entered into an agreement to acquire Valencia Technologies for an undisclosed amount, expanding its urology portfolio.
CEO of Boston Scientific Michael Mahoney
CEO of Penumbra Adam Elsesser
CEO of Valencia Technologies Jim Surek
Last week’s tracker: Surgerii, Spiro Medical & more
Smith+Nephew agreed to acquire Integrity Orthopaedics for up to $450M
Under the agreement, Smith+Nephew will purchase Integrity Orthopaedics for an upfront cash payment of $225M, with further performance-linked payments of up to $225M payable over the next five years.
The acquisition is expected to strengthen Smith+Nephew’s shoulder repair portfolio and is part of the company’s plan to grow its presence in sports medicine, with a focus on RCR systems. It is anticipated to close before the end of January 2026.
CEO of Smith+Nephew Deepak Nath
Co-Founder and CEO of Integrity Orthopaedics Tom Westling
4DMedical secured $150M backing from institutional investors
The institutional placement was priced at $3.80 per share – a discount to the company’s closing price yesterday of $4.29 per share.
The placement attracted strong support from existing shareholders with applications at “multiple times” the placement size, while also securing cornerstone investments from new, global long-only institutional shareholders.
CEO Andreas Fouras
Inquis Medical announced $75M Series C financing to scale AVENTUS
The investment, provided by an undisclosed strategic investor, will be used to accelerate nationwide commercial expansion of the AVENTUS Thrombectomy System and advance the company’s next-generation product pipeline.
This latest round builds upon the momentum established by a $40M Series B financing led by Marshall Wace, completed in August 2024.
Co-CEOs Vahid Saadat and Mojgan Saadat
Distalmotion secured funding to support Dexter rollout in ASCs
The company secured a strategic investment from Johnson & Johnson’s JJDC venture capital arm. The financing, for which the company did not disclose the amount, follows a $150M Series G round closed in November.
It adds further support for Distalmotion’s push to bring its purpose-built Dexter surgical robot into ambulatory surgery centers.
CEO Greg Roche
AI4Eyes closed C$6.5M funding to advance AI-driven eye care innovation
The combined financings, $3.7M CAD internal financing round from existing investors together with $2.8M CAD in non-dilutive funding, bring total new capital secured during the period to $6.5M CAD.
The funding strengthens the company’s balance sheet and supports its next phase of growth as it advances its roadmap toward the commercialization of regulated, AI-powered eye care solutions.
CEO Tara Akhavan
TempraMed closed C$2.5M fully subscribed private placement
The company announced the fully subscribed closing of its previous non-brokered private placement, issuing 3,322,153 units at a price of $0.76 per Unit for aggregate gross proceeds of CAD$2,524,836.28.
Each Unit consists of one common share in the capital of the Company and one Share purchase warrant of the Company. Each Warrant will entitle the holder thereof to acquire one additional Share at a price of $1.00 per Warrant Share until July 12, 2027.
CEO Ron Nagar
PulseAI secured seed funding to advance AI-driven ECG diagnostics
The investment will enable the company to scale deployment of its AI-ECG technology and advance its pathway through US FDA 510(k) clearance.
The round was led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute.
Founder and CEO Alan Kennedy
